Evaluation of the clinical, hemodynamic and neurohormonal response to levosimendan administration in decompensated heart failure patients. One-month follow-up;Avaliação do perfil da resposta clínica, hemodinâmica e neurohormonal à administração de levosimendan na insuficiêneia cardíaca crónica agudizada. Seguimento de uni mês

Revista Portuguesa de Cardiologia

Volumn 26, Issue 7-8, 2007, Pages 717-726

  Sargento, Luís ^a   Brito, Dulce ^b   Matias, J Sampaio ^b   Madeira, Hugo ^b  

^a Hospital Sta Maria

^b NONE

Author keywords

Chronic heart failure; Levosimendan; NT ProBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; LEVOSIMENDAN; NEUROHORMONE; SPIRONOLACTONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG SCREENING; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HEART HEMODYNAMICS; HEART INDEX; HUMAN; MALE; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; WEIGHT REDUCTION;

BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOTONIC AGENTS; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART RATE; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PYRIDAZINES;

EID: 34748819972     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Haikala H, Nissinen E, Etematzadeh E, Levijoki J, Linden B. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 1995;25:794-801.
2. Mebazaa A, Barraud D, Elschbillig S. Randomized Clinical Trials with Levosimendan. Am J Cardiol 2005;96[suppl]: 74G-79G.
3. Parissis JT, Panou F, Farmakis D, Adamopoulos S, Filippatos G, Paraskevaidis I, Venetsanou K, Lekakis J, Kremastinos D. Effects of Levosimendan on Markers of Left Ventricular Diastolic Function and Neurohormonal Activation in Patients With Advanced Heart Failure. Am J Cardiol 2005;96:423-426.
4. Kyrzopoulos S, Adamopoulos S, Parissis JT, Rassias J, Kostakis G, Iliodromitis E, Degiannis D, Kremastinos D. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Int J of Cardiol 2005; 99: 409-413.
5. Figgitt DP, Gillies PS, Goa KL. Levosimendan. Drugs 2001;61:613-627.
6. Greenberg B, Borghi C, Perrone S. Pharmacological approaches for decompensated heart failure: a role for the calcium sensitizer, levosimendan? Eur J Heart Fail 2003;5:13-21.
7. Maytin M, Colucci WS. Cardioprotection: A New Paradigm in the Management of Acute Heart Failure Syndromes. Am J Cardiol 2005;96[suppl]:26G-31G.
8. Parissis JT, Adamopoulos S, Antoniades C, Kostakis G, Rigas A, Kyrzopoulos S, Iliodromitis E, Kremastinos D. Effects of Levosimendan on Circulating Proinflammatory Cytokines and Soluble Apoptosis Mediators in Patients With Decompensated Advanced Heart Failure. Am J Cardiol 2004;93:1309-1312.
9. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, Nyquist O, Remme WJ. Hemodynamic and neurohormonal effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1903-1912.
10. Follath F, Cleland JGF, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L, for the Steering Committee and Investigators of the Levosimendan Infusion Versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double blind trial. Lancet. 2002; 360:196-202.
11. Moertl D, Berger R, Huelsmann M, Bojic A, Pacher R. Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure. European Journal of Heart Failure (2005) Online pre-publication.
12. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, Nyquist O, Remme WJ. Hemodynamic and neurohormonal effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1903-1912.
13. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, LeJemtel TH, Loh E, Nioklas J, Ogilby D, Singh BN, Smith W. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation. 2000;102: 2222-2227.
14. Kivikko M, Antila S, Eha J, et al. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol 2002;42:43-51.